449 related articles for article (PubMed ID: 30548438)
1. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy.
Al-Zaidy S; Pickard AS; Kotha K; Alfano LN; Lowes L; Paul G; Church K; Lehman K; Sproule DM; Dabbous O; Maru B; Berry K; Arnold WD; Kissel JT; Mendell JR; Shell R
Pediatr Pulmonol; 2019 Feb; 54(2):179-185. PubMed ID: 30548438
[TBL] [Abstract][Full Text] [Related]
2. AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a Prospective Natural History Cohort.
Al-Zaidy SA; Kolb SJ; Lowes L; Alfano LN; Shell R; Church KR; Nagendran S; Sproule DM; Feltner DE; Wells C; Ogrinc F; Menier M; L'Italien J; Arnold WD; Kissel JT; Kaspar BK; Mendell JR
J Neuromuscul Dis; 2019; 6(3):307-317. PubMed ID: 31381526
[TBL] [Abstract][Full Text] [Related]
3. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy.
Mendell JR; Al-Zaidy S; Shell R; Arnold WD; Rodino-Klapac LR; Prior TW; Lowes L; Alfano L; Berry K; Church K; Kissel JT; Nagendran S; L'Italien J; Sproule DM; Wells C; Cardenas JA; Heitzer MD; Kaspar A; Corcoran S; Braun L; Likhite S; Miranda C; Meyer K; Foust KD; Burghes AHM; Kaspar BK
N Engl J Med; 2017 Nov; 377(18):1713-1722. PubMed ID: 29091557
[TBL] [Abstract][Full Text] [Related]
4. From Clinical Trials to Clinical Practice: Practical Considerations for Gene Replacement Therapy in SMA Type 1.
Al-Zaidy SA; Mendell JR
Pediatr Neurol; 2019 Nov; 100():3-11. PubMed ID: 31371124
[TBL] [Abstract][Full Text] [Related]
5. Impact of Age and Motor Function in a Phase 1/2A Study of Infants With SMA Type 1 Receiving Single-Dose Gene Replacement Therapy.
Lowes LP; Alfano LN; Arnold WD; Shell R; Prior TW; McColly M; Lehman KJ; Church K; Sproule DM; Nagendran S; Menier M; Feltner DE; Wells C; Kissel JT; Al-Zaidy S; Mendell J
Pediatr Neurol; 2019 Sep; 98():39-45. PubMed ID: 31277975
[TBL] [Abstract][Full Text] [Related]
6. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.
Day JW; Finkel RS; Chiriboga CA; Connolly AM; Crawford TO; Darras BT; Iannaccone ST; Kuntz NL; Peña LDM; Shieh PB; Smith EC; Kwon JM; Zaidman CM; Schultz M; Feltner DE; Tauscher-Wisniewski S; Ouyang H; Chand DH; Sproule DM; Macek TA; Mendell JR
Lancet Neurol; 2021 Apr; 20(4):284-293. PubMed ID: 33743238
[TBL] [Abstract][Full Text] [Related]
7. Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.
Dabbous O; Maru B; Jansen JP; Lorenzi M; Cloutier M; Guérin A; Pivneva I; Wu EQ; Arjunji R; Feltner D; Sproule DM
Adv Ther; 2019 May; 36(5):1164-1176. PubMed ID: 30879249
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients.
Malone DC; Dean R; Arjunji R; Jensen I; Cyr P; Miller B; Maru B; Sproule DM; Feltner DE; Dabbous O
J Mark Access Health Policy; 2019; 7(1):1601484. PubMed ID: 31105909
[No Abstract] [Full Text] [Related]
9. Onasemnogene Abeparvovec-xioi: Gene Therapy for Spinal Muscular Atrophy.
Stevens D; Claborn MK; Gildon BL; Kessler TL; Walker C
Ann Pharmacother; 2020 Oct; 54(10):1001-1009. PubMed ID: 32204605
[TBL] [Abstract][Full Text] [Related]
10. Association between the SMN2 gene copy number and clinical characteristics of patients with spinal muscular atrophy with homozygous deletion of exon 7 of the SMN1 gene.
Zarkov M; Stojadinović A; Sekulić S; Barjaktarović I; Perić S; Keković G; Drasković B; Stević Z
Vojnosanit Pregl; 2015 Oct; 72(10):859-63. PubMed ID: 26665550
[TBL] [Abstract][Full Text] [Related]
11. Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: A cohort study.
Aragon-Gawinska K; Seferian AM; Daron A; Gargaun E; Vuillerot C; Cances C; Ropars J; Chouchane M; Cuppen I; Hughes I; Illingworth M; Marini-Bettolo C; Rambaud J; Taytard J; Annoussamy M; Scoto M; Gidaro T; Servais L
Neurology; 2018 Oct; 91(14):e1312-e1318. PubMed ID: 30158155
[TBL] [Abstract][Full Text] [Related]
12. Nusinersen for spinal muscular atrophy type 1: Real-world respiratory experience.
Lavie M; Diamant N; Cahal M; Sadot E; Be'er M; Fattal-Valevski A; Sagi L; Domany KA; Amirav I
Pediatr Pulmonol; 2021 Jan; 56(1):291-298. PubMed ID: 33111497
[TBL] [Abstract][Full Text] [Related]
13. One Year of Newborn Screening for SMA - Results of a German Pilot Project.
Vill K; Kölbel H; Schwartz O; Blaschek A; Olgemöller B; Harms E; Burggraf S; Röschinger W; Durner J; Gläser D; Nennstiel U; Wirth B; Schara U; Jensen B; Becker M; Hohenfellner K; Müller-Felber W
J Neuromuscul Dis; 2019; 6(4):503-515. PubMed ID: 31594245
[TBL] [Abstract][Full Text] [Related]
14. Clinical Outcomes in Patients with Spinal Muscular Atrophy Type 1 Treated with Nusinersen.
de Holanda Mendonça R; Jorge Polido G; Ciro M; Jorge Fontoura Solla D; Conti Reed U; Zanoteli E
J Neuromuscul Dis; 2021; 8(2):217-224. PubMed ID: 33459657
[TBL] [Abstract][Full Text] [Related]
15. Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening.
Glascock J; Sampson J; Haidet-Phillips A; Connolly A; Darras B; Day J; Finkel R; Howell RR; Klinger K; Kuntz N; Prior T; Shieh PB; Crawford TO; Kerr D; Jarecki J
J Neuromuscul Dis; 2018; 5(2):145-158. PubMed ID: 29614695
[TBL] [Abstract][Full Text] [Related]
16. Two Japanese Patients With SMA Type 1 Suggest that Axonal-SMN May Not Modify the Disease Severity.
Yamada H; Nishida Y; Maihara T; Sa'adah N; Harahap NI; Nurputra DK; Ar Rochmah M; Nishimura N; Saito T; Kubo Y; Saito K; Nishio H
Pediatr Neurol; 2015 Jun; 52(6):638-41. PubMed ID: 25838041
[TBL] [Abstract][Full Text] [Related]
17. The gene copy ratios of SMN1/SMN2 in Japanese carriers with type I spinal muscular atrophy.
Diep Tran T; Kroepfl T; Saito M; Nagura M; Ichiseki H; Kubota M; Toda T; Sakakihara Y
Brain Dev; 2001 Aug; 23(5):321-6. PubMed ID: 11504604
[TBL] [Abstract][Full Text] [Related]
18. Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen.
Aragon-Gawinska K; Daron A; Ulinici A; Vanden Brande L; Seferian A; Gidaro T; Scoto M; Deconinck N; Servais L;
Dev Med Child Neurol; 2020 Mar; 62(3):310-314. PubMed ID: 31799720
[TBL] [Abstract][Full Text] [Related]
19. Risdiplam in Type 1 Spinal Muscular Atrophy.
Baranello G; Darras BT; Day JW; Deconinck N; Klein A; Masson R; Mercuri E; Rose K; El-Khairi M; Gerber M; Gorni K; Khwaja O; Kletzl H; Scalco RS; Seabrook T; Fontoura P; Servais L;
N Engl J Med; 2021 Mar; 384(10):915-923. PubMed ID: 33626251
[TBL] [Abstract][Full Text] [Related]
20. Natural history of infantile-onset spinal muscular atrophy.
Kolb SJ; Coffey CS; Yankey JW; Krosschell K; Arnold WD; Rutkove SB; Swoboda KJ; Reyna SP; Sakonju A; Darras BT; Shell R; Kuntz N; Castro D; Parsons J; Connolly AM; Chiriboga CA; McDonald C; Burnette WB; Werner K; Thangarajh M; Shieh PB; Finanger E; Cudkowicz ME; McGovern MM; McNeil DE; Finkel R; Iannaccone ST; Kaye E; Kingsley A; Renusch SR; McGovern VL; Wang X; Zaworski PG; Prior TW; Burghes AHM; Bartlett A; Kissel JT;
Ann Neurol; 2017 Dec; 82(6):883-891. PubMed ID: 29149772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
